Behçet's syndrome: Disease manifestations, management, and advances in treatment

Nature Clinical Practice Rheumatology

Volumn 3, Issue 3, 2007, Pages 148-155

  Yazici, Hasan ^a   Fresko, Izzet ^a   Yurdakul, Sebahattin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ACYLTRANSFERASE; ALPHA ENOLASE; ALPHA2A INTERFERON; ANTINUCLEAR ANTIBODY; APOLIPOPROTEIN E; AZAPROPAZONE; CARDIOLIPIN ANTIBODY; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHEMOKINE RECEPTOR CXCR2; COLCHICINE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE; ETANERCEPT; GLUTATHIONE TRANSFERASE M1; HLA B51 ANTIGEN; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 1BETA; MANNOSE BINDING LECTIN; METHYLPREDNISOLONE ACETATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; THALIDOMIDE; TRANSFER FACTOR; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN;

ACNE; ARTHRITIS; ATHEROSCLEROSIS; BEHCET DISEASE; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; EPIDEMIOLOGICAL DATA; ERYTHEMA NODOSUM; EYE DISEASE; GASTROINTESTINAL DISEASE; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HYPERCOAGULABILITY; INCIDENCE; MARKER GENE; MEDICAL RESEARCH; MORTALITY; MUSCULOSKELETAL DISEASE; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOPHYSIOLOGY; PATIENT CARE; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REACTIVE ARTHRITIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUPERFICIAL THROMBOPHLEBITIS; TERATOGENICITY; THROMBOPHILIA; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS;

BEHCET SYNDROME; DISEASE PROGRESSION; HLA-B ANTIGENS; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33947285787     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0436     Document Type: Review

References (63)

1. Sakane T et al. (1999) Behcet's disease N Engl J Med 41:1284-1291
2. Azizierli G et al. (2003) Prevalence of Behcet's disease in Istanbul, Turkey. Int J Dermatol 42: 803-806
3. Kone-Paut I et al. (1998) Clinical features of Behcet's disease in children: An international collaborative study of 86 cases. J Pediatr 132: 721-725
4. Yurdakul S et al. (1996) Gastrointestinal involvement in Behcet's syndrome: A controlled study. Ann Rheum Dis 55: 208-210
5. Yazici H et al. (1984) A comparative study of the pathergy reaction among Turkish and British patients with Behcet's disease. Ann Rheum Dis 43: 74-75
6. Saylan T et al. (1999). Behcet's disease in the Middle East. Clinical Dermatol 17: 209-223
7. Mat CM et al. (2006) The frequency of scarring after genital ulcers in Behcet's syndrome: A prospective study. Inter J Dermatol 45: 554-556
8. Ergun T et al. (1998) Histopathologic features of the spontaneous pustular lesions of Behcet's syndrome. Int J Dermatol 37: 194-196
9. Tüzün Y et al. (1979) The usefulness of the nonspecific skin hyperreactivity (the pathergy test) in Behcet's disease in Turkey. Acta Derm Venerol 59: 77-79
10. Tugal-Tutkun I et al. (2004) Uveitis in Behcet disease: An analysis of 880 patients. Am J Ophthalmol 138: 373-380
11. Yurdakul S et al. (1983) The arthritis of Behcet's disease: A prospective study. Ann Rheum Dis 42: 505-515
12. Yazici H et al. (1981) A controlled survey of sacroiliitis in Behcet's disease. Ann Rheum Dis 40: 558-559
13. Diri E et al. (2001) Papulopustular skin lesions are seen more frequently in patients with Behcet's syndrome who have arthritis: A controlled and masked study. Ann Rheum Dis 60: 1074-1076
14. Akman-Demir G et al. (11999) Clinical patterns of neurological involvement in Behcet's disease: Evaluation of 200 patients. Brain 122: 2171-2182
15. Siva A et al. (2001) Behcet's disease: Diagnostic and prognostic aspects of neurological involvement. J Neurol 248: 95-103
16. Koc Y et al. (1992) Vascular involvement in Behcet's disease. J Rheumatol 19: 402-410
17. Lie JT (1992) Vascular involvement in Behcet's disease: Arterial and venous and vessels of all sizes. J Rheumatol 19: 341-343
18. Hamuryudan V et al. (2004) Pulmonary artery aneurysms in Behcet syndrome. Am J Med 117: 867-870
19. Korman U et al. (2003) Enteroclysis findings of intestinal Behcet disease: A comparative study with Crohn disease. Abdom Imaging 28: 308-312
20. Chun SI et al. (1990) Histopathology of cutaneous lesions in Behcet's syndrome. J Dermatol 17: 333-341
21. Demirkesen C et al. (2001) Clinicopathologic evaluation of nodular cutaneous lesions of Behcet syndrome. Am J Clin Pathol 116: 341-346
22. Matsumoto T et al. (1991) Vasculo-Behcet's disease: A pathologic study of eight cases. Hum Pathol 22: 45-51
23. Hadfield MG et al. (1997) Neuro-Behcet's disease. Clin Neuropathol 16: 55-60
24. Ehrlich GE (1997) Vasculitis in Behcet's disease. Int Rev Immunol 14: 81-88
25. Mege JL et al. (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20: 1544-1549
26. Ben Ahmed M et al. (2004) Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behcet's disease. Arthritis Rheum 50: 2291-2295
27. H1 polarization of the immune response in Behcet's disease: A putative pathogenetic role of interleukin-12. Arthritis Rheum 42: 1967-1974
28. Melikoglu M et al. (2006) Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. J Immunol 177: 6415-6421
29. Lee KH et al. (2003) Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behcet's disease. Arthritis Rheum 48: 2025-2035
30. Espinosa G et al, (2002) Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 112: 37-43
31. Yurdakul S et al. (2005) Fibrinolytic activity and d-dimer levels in Behcet's syndrome. Clin Exp Rheumatol 23 (Suppl 38): S53-S58
32. Tunc R et al. (2002) Target organ associations in Turkish patients with Behcet's disease: A cross sectional study by exploratory factor analysis. J Rheumatol 29: 2393-2396
33. Hatemi G et al. (2004) The pustular skin lesions in Behcet's syndrome are not sterile. Ann Rheum Dis 63: 1450-1452
34. Fresko I et al. (2005) Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behcet's syndrome. Clin Exp Rheumatol 23 (Suppl 38): S67-S70
35. Krause I et al. (1999) Disease patterns of patients with Behcet's disease demonstrated by factor analysis. Clin Exp Rheumatol 17: 347-350
36. Tunc R et al. (2004) Cerebral venous thrombosis is associated with major vessel disease in Behcet's syndrome. Ann Rheum Dis 63: 1693-1694
37. Gul A (2005) Behcet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 4: 81-83
38. Yazici H and Fresko I (2005) Behcet's disease and other autoinflammatory conditions: What's in a name? Clin Exp Rheumatol 23 (Suppl 38): S1-S2
39. Gul A et al. (2001) Linkage mapping of a novel susceptibility locus for Behcet's disease to chromosome 6p22-23. Arthritis Rheum 44: 2693-2696
40. Fresko I et al. (1998) Genetic anticipation in Behcet's syndrome. Ann Rheum Dis 57: 45-48
41. Karasneh J et al. (2005) Whole-genome screening for susceptibility genes in multicase families with Behçet's disease. Arthritis Rheum 52: 1836-1842
42. Molinari N et al (2003) Identification of an autosomal recessive mode of inheritance in paediatric Behcet's families by segregation analysis. Am J Med Genet 122: 115-118
43. Saruhan-Direskeneli G et al. (2004) Expression of KIR and C-type lectin receptors in Behçet's disease. Rheumatology (Oxford) 43: 423-427
44. Inanc N et al. (2005) Serum mannose-binding lectin levels are decreased in Behcet's disease and associated with disease severity. J Rheumatol 32: 287-291
45. Kural-Seyahi E et al. (2003) The long-term mortality and morbidity of Behcet syndrome: A 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82: 60-76
46. Seyahi E et al. (2004) Coronary atherosclerosis in Behcet's syndrome: A pilot study using electron-beam computed tomography. Rheumatology (Oxford) 43: 1448-1450
47. Hamuryudan V et al. (1997) Azathioprine in Behcet's syndrome: Effects on long-term prognosis. Arthritis Rheum 40: 69-74
48. Mat C et al. (2006) Double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology (Oxford) 45: 348-352
49. Melikoglu M et al. (2005) Short-term trial of etanercept in Behcet's disease: A double blind, placebo controlled study. J Rheumatol 32: 98-105
50. Alpsoy E et al. (2002) Interferon alfa-2a in the treatment of Behcet disease: A randomized placebo-controlled and double-blind study. Arch Dermatol 138: 467-471
51. Sharquie KE et al. (2002) Dapsone in Behcet's disease: A double-blind, placebo-controlled, cross-over study. J Dermatol 29: 267-279
52. Yurdakul S et al. (2001) Double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 44: 2686-2692
53. Hamuryudan V et al. (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128: 443-450
54. Moral F et al. (1995) Inefficacy of azapropazone in the acute arthritis of Behcet's syndrome: A randomized, double blind, placebo controlled study. Clin Exp Rheumatol 13: 493-495
55. Yazici H et al. (1990) A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 322: 281-285
56. Masuda K et al. (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1: 1093-1096
57. Davies UM et al. (1988) Treatment with acyclovir does not affect orogenital ulcers in Behcet's syndrome: A randomized double-blind trial. Br J Rheumatol 27: 300-302
58. Aktulga E et al. (1980) A double blind study of colchicine in Behcet's disease. Haematologica 65: 399-402
59. Denman AM et al. (1979) Failure of transfer factor in the treatment of Behcets syndrome: A double-blind trial. In Behcet's Syndrome, 227-289 (Eds Lehner T and Barnes CG) London: Academic Press
60. Kotter I et al. (2004) The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 33: 320-335
61. Tugal-Tutkun I et al. (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: An open-label trial. Arthritis Rheum 52: 2478-2484
62. Ohno S et al. (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31: 1362-1368
63. Kahraman O et al. (2003) Long-term course of deep venous trombosis in patients with Behcet's disease [abstract]. Arthritis Rheum 48 (Suppl): S385